Roche and Hansoh Pharmaceutical Group announced a second antibody-drug conjugate (ADC) collaboration, with the companies saying the deal could generate more than $15 billion in value. The agreement targets a portfolio of ADCs “across multiple cancer types,” building on Hansoh’s ADC technology platform and Roche’s target discovery capabilities.